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Lung cancerMitogen-inducible gene 6 (MIG6) is a tumor suppressor implicated in the development of human cancers; how-
ever, the regulatory mechanisms ofMIG6 remain unknown. Here, using a yeast two-hybrid screen, we identiﬁed
DnaJ homolog subfamily Bmember I (DNAJB1) as a novelMIG6-interacting protein.We found that DNAJB1 binds
to and decreases MIG6 protein, but not mRNA, levels. DNAJB1 overexpression dosage-dependently decreased
MIG6 protein levels. Conversely, DNAJB1 knockdown increased MIG6 protein levels. DNAJB1 destabilizes
MIG6 by enhancing K48-linked ubiquitination of MIG6. However, knocking-down of DNAJB1 reduced the
ubiquitination of MIG6. DNAJB1 positively regulates the epidermal growth factor receptors (EGFR) signaling
pathway via destabilization of MIG6; however, DNAJB1 knockdown diminishes activation of EGFR signaling as
well as elevation of MIG6. Importantly, the increased levels of MIG6 by DNAJB1 knockdown greatly enhanced
the geﬁtinib sensitivity in A549 cells. Thus, our study provides a new molecular mechanism to regulate EGFR
signaling through modulation of MIG6 by DNAJB1 as a negative regulator.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Mitogen-inducible gene 6 (MIG6/RALT/gene33/Errﬁ1) is a negative
regulator of epidermal growth factor receptors (EGFRs) by inhibition
of their tyrosine kinase activities [1]. MIG6 also binds to and inhibits
cdc42 activity via its CRIB domain, which leads to inhibition of hepato-
cyte growth factor-induced cell migration [2]. It was reported that
MIG6 is downregulated in human tumors, including breast carcinoma,
hepatocellular carcinoma, and thyroid cancer [2–4].MIG6-deﬁcient mice
displayed hyperactivation of EGFR and sustained mitogen-activated
protein kinase (MAPK) signaling activation [1,5]. Furthermore, MIG6-
deﬁcient mice develop spontaneous tumors in various organs and are
highly susceptible to chemically-induced skin tumors [6]. Strikingly, inhi-
bition of endogenous EGFR signaling using the EGFR small inhibitor geﬁ-
tinib (Iressa) or replacement of wild-type EGFR with the kinase-deﬁcient
protein encoded by the hypomorphic EGFR allele completely rescued skinB member I; MIG6, mitogen-
s
y andMolecular Biology, Yonsei
f Korea.
i), yhgeun@yuhs.acdefects inMIG6 knockout (KO)mice [6]. Recently,MIG6was shown to act
as a tumor suppressor in endometrial cancers associated with PTEN deﬁ-
ciency by inhibiting estrogen signaling in the uterus [7]. Ablation ofMIG6
in the murine uterus leads to endometrial hyperplasia and estrogen-
induced endometrial cancer [8]. More recently, it has been shown that
MIG6mediates progesterone action and inhibits ERK1/2 signaling to sup-
press endometrial cancer development and progression that is associated
with PTEN deﬁciency [9]. These demonstrate that the tumor suppressor
MIG6 is a speciﬁc negative regulator of EGFR.
MIG6 is induced as an immediate early response gene by a variety of
stimuli, including growth factors, fetal calf serum, insulin, hypoxia, and
stress [10]. It has been also reported that various stressors induce MIG6
transcription [11–14]. Moreover, MIG6 is induced by EGF treatment and
functions as a feedback inhibitor of EGFR signaling, regulating receptor
activation and stability [1]. Therefore, MIG6 induction is a critical step
for cells to sense external stimuli. Although MIG6 clearly acts as a
tumor suppressor and its downregulation correlateswith human cancer
development, the molecular mechanisms regarding how MIG6 levels
are regulated remain unknown.
The dynamic exchange of multiple chaperone proteins during cellu-
lar stress events occurs in important cellular reactions including DNA
replication, protein degradation and translocation, cell signaling, and
apoptosis [15]. When cells are exposed to environmental stress, such
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play a role by regulating the correct folding, degradation, localization,
and function of target proteins [16,17]. HSPs are classiﬁed based on
their relative molecular weight. There are ﬁve major HSP proteins:
HSP90, HSP70, HSP60, HSP40, and small heat shock proteins [18].
DNAJB1 (also called hDj-1) is a member of the HSP40 protein family
[19] and interacts withmultiple proteins in the cytoplasm. For example,
DNAJB1 interacts with heat HSP70 and induces its ATPase activity,
which stimulates the association between HSP70 and Hsc70-
interactingprotein (HIP) [20]. DNAJB1 interactswithHsc70 to sequester
p53 in the cytosol [21]. Moreover, the HSP70-DNAJB1 chaperone was
found to prevent nitric oxide-induced apoptosis in both macrophages
and COS-7 cells [22,23]. In accordance with these ﬁndings, we recently
reported that DNAJB1 binds to and destabilizes PDCD5 (programmed
cell death 5), ultimately leading to suppression of p53-mediated
apoptosis [24]. Collectively, these suggest that DNAJB1 may regulate
the stability of various proteins in the cytoplasm to maintain cellular
homeostasis.
In this study, we found that DNAJB1 binds to and destabilizes the
MIG6 protein by enhancing ubiquitin-dependent proteasomal degrada-
tion of MIG6, which positively affects the EGFR signaling pathway.
Moreover, we provide evidence that DNAJB1 suppressesMIG6 stabiliza-
tion to enhance lung cancer cell proliferation.We identiﬁedDNAJB1 as a
negative regulator ofMIG6 function and propose that theDNAJB1-MIG6
regulatory network plays an important role in the growth of lung cancer
cells.
2. Materials and methods
2.1. Cell culture and reagents
Human lung adenocarcinoma cell line A549, human colorectal carci-
noma cell line HCT116 were purchased from and authenticated by the
Korean Cell Line Bank (Seoul, Korea) using short tandem repeat analy-
sis. These cells were used within 6 months of purchase. All cells were
cultured in Dulbecco's modiﬁed Eagle's medium (DMEM) supplement-
ed with 10% (v/v) fetal bovine serum (FBS), 100 units/ml penicillin, and
0.1 mg/ml streptomycin (Hyclone, Logan, UT, USA) at 37 °C under 5%
CO2. MG132 and cycloheximide (CHX) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). MG132 and CHXwere prepared in dimethyl
sulfoxide (DMSO) (Sigma-Aldrich). EGF was purchased from ATGen
(Seongnam-si, Gyeonggi-do, Korea) and prepared in 1× PBS. Geﬁtinib
was purchased from LC Laboratories (Woburn, MA, USA) and prepared
in DMSO (Sigma-Aldrich). Lipofectamine 2000 was used for overexpres-
sion constructs and Lipofectamine RNAi Max was used for siRNA (Life
Technologies, Grand Island, NY, USA).
2.2. Plasmids and small-interfering RNAs (siRNAs)
Wild-type, full-length MIG6 and DNAJB1 constructs were generated
by PCR and cloned into the pSG5-KF2M1-FLAG, -Myc, or -HA (Sigma-
Aldrich), and pGEX4T-1 plasmid vectors (GE healthcare, Piscataway,
NJ, USA). All plasmid constructs were veriﬁed by DNA sequencing. For
siRNA transfection, cells were plated at 60–70% conﬂuency and
transfected using Lipofectamine RNAi MAX (Life Technologies) with
20 pM siRNA following the manufacturer's protocol. After 4 h, the
media was changed, and cells were incubated for 2 days and treated
with indicating reagents. Sequences of siRNAs; Sense 5′-CCUCGUGCCG
UUCCAUCAGGUAGUU-3′, Antisense 5′-CUACCUGAUGGAACGGCACG
AGGUU-3′ (Negative Control); Sense 5′-CUUUCGUACUGCUGAAUG
UUU-3′, Antisense 5′-CAUUCAGCAGUACGAAAGUU-3′ (siDNAJB1 #3);
Sense 5′-GGACUAUGGACUCUUUCAAUU 3′, Antisense 5′-UUGAAAGA
GUCCAUAGUCCUU-3′ (siDNAJB1 #4); Sense 5′-CCUAACUAGCUCAGAU
ACAUU-3′, Antisense 5′-UGUAUCUGACUAGUUAGGUU-3′ (siMIG6
#1); Sense 5′-GUUACUUGGCAACCAUAUUUU-3′, Antisense 5′-AAUA
UGGUUGCCAAGUAACUU-3′ (siMIG6 #4); Sense 5′-GAAGCAAUUAGCUAUGUGAUU-3′, Antisense 5′-UCACAUAGCUAAUUGCUUCUU-3′
(siMIG6 #5).
2.3. Western blotting, immunoprecipitation, and antibodies
Cells were washed with cold phosphate-buffered saline (PBS) and
collected. Cell extracts were prepared with lysis buffer [50 mmol/L
Tris–Cl (pH 7.5), 150 mmol/L NaCl, 1% NP40, 10 mmol/L NaF, 10
mmol/L sodium pyrophosphate, and protease inhibitors] and incubated
on ice for 30 min. The lysates were centrifuged at 20,000 ×g for 10 min
at 4 °C. Total cell lysate protein was incubated with the anti-Myc (Cell
signaling) or anti-Flag (Sigma) antibodies and with 20 μL of protein
A/G agarose overnight at 4 °C. After washing three times with agarose
bead washing buffer, the immunoprecipitated protein–antibody com-
plexes were separated on SDS-PAGE gel and transferred to nitrocellu-
lose membranes. The membranes were blocked by incubating for 2 h
in 5% w/v non-fat DifcoTM skim milk blocking buffer with 1× PBS
with Tween-20 (PBST). The blocked membranes were incubated
overnight at 4 °C with the indicated antibodies. After washing with
1 × PBST, themembranes were incubated with the appropriate second-
ary anti-rabbit or anti-mouse horseradish peroxidase-conjugated anti-
body (Thermo Scientiﬁc, Rockford, IL, USA) for 1 h, and visualized
using LAS-3000 system (Fujiﬁlm, Stamford, CT, USA) with an enhanced
chemiluminescence detection reagent (Thermo Scientiﬁc). The antibod-
ies were used anti-Mig6, anti-HSP40, anti-HA (Santacruz), anti-Flag,
anti-β-actin (Sigma–Aldrich), anti-Myc, anti-phospho-EGFR (Tyrosine
1068), anti-EGFR, anti-phospho-ERK (Serine 42/44), anti-ERK, and
anti-cleaved caspase-3 (Cell Signaling, Danvers, MA, USA), anti-PARP-
1 (BD Transduction Laboratories, Lexington, KY, USA). Western blot
bands were quantiﬁed using ImageJ software (free download available
at http://rsbweb.nih.gov/ij/). Density value was normalized by each
β-actin band.
2.4. RNA isolation and quantitative RT-PCR
Total RNAwas extracted using the Trizol reagent following the stan-
dard protocol (TAKARA, Shimogyo-ku, Kyoto, Japan). Then, cDNA was
prepared using random hexamer primers (Chromogen). PCR was per-
formed using the following forward and reverse primers: F-5′-GATG
GCATGGACTGTGGTCA-3′, R-5′GCAATGCCTCCTGCACCACC-3′ (human
GAPDH); F-5′-CTG GAG CAG TCG CAG TGA G-3′, R-5′-GCC ATT CAT
CGG AGC AGA TTT G-3′ (human Mig-6); F-5′-TCT TGA TGT CTG GGG
AAT CCT T-3′, R-5′-CCA GTC ACC CAC GAC CTT C-3′ (human DNAJB1
RT-1); F-5′-CTC TGG ACG GCA GGA CGA TA-3′, and R-5′-TCT TGA TGT
CTG GGG AAT CCT T-3′ (human DNAJB1 RT-2). Concentration of cDNA
was normalized using GAPDH.
2.5. In vivo ubiquitination assay
HCT116 cells were co-transfected with plasmids encoding HA-Ub,
HA-Ub K48, HA-Ub K63, Myc-Mig6 or Flag-DNAJB1. After 48 h, whole
cell lysates were treated with MG132 for 6 h and subsequently proc-
essed for immunoprecipitation with anti-Myc antibody. Ubiquitination
of Myc-MIG6 was visualized by Western blotting with an anti-HA
antibody.
2.6. MTT assay
Cell viability was determined with the conventional MTT reduction
assay. First, 5 × 103–1 × 104 cells were seeded in a 96-well plate. After
overnight incubation, cells were transfected with indicated plasmids
for 30 h, and the cells were treated with EGF or geﬁtinib for another
48 h. Cells were then treated with 15 μMMTT solution (Sigma-Aldrich)
for 90min at 37 °C. The formation of formazanwas resolvedwith DMSO
solution for 30 min with shaking. The absorbance was recorded at
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reader (Model 550, BIO-RAD Laboratories, Hercules, CA, USA).
2.7. TUNEL assay
For the detection of apoptosis in cells, DNA fragmentation was eval-
uated by a TUNEL assay using the HT Titer TACS Assay Kit (Trivigen,Fig. 1. DNAJB1 binds to MIG6 and decreases its protein levels. (A) DNAJB1 interacts with MIG6.
cell lysates were imunoprecipitated and immunoblotted with the indicated antibodies (left pa
analyzed using autoradiography (right panel). (B) Endogenous DNAJB1 interacts with MIG6. Im
domain (180–210 a.a.) of DNAJB1 interacts with MIG6. Schematic diagrams of Flag-DNAJB1
transfected with the Myc-MIG6 and Flag-DNAJB1 plasmids as indicated. Cell lysates were imm
teraction and binding (CRIB) domain of MIG6 interacts with DNAJB1. Schematic diagrams of My
co-transfectedwith the Flag-DNAJB1 andMyc-MIG6 plasmids as indicated. Cell lysates were im
from three independent experiments are shown.Gaithersburg, MD, USA) according to the manufacturer's instructions.
Brieﬂy, the cells were ﬁxed with 3.7% buffered formaldehyde solution
for 7 min, washed with PBS, permeabilized with 100% methanol for
20 min, washed with PBS twice, digested with proteinase K for
15 min, quenched with 3% hydrogen peroxide, washed with distilled
water, labeled with deoxynucleotidyl transferase, incubated at 37 °C
for 90 min, and then treated with stop buffer. The cells were incubatedFlag-tagged DNAJB1 andMyc-tagged MIG6 were co-transfected into HCT116 cells. Whole
nel). GST pull downs were performed overnight at 4 °C. Bound proteins were eluted and
munoprecipitation assays were performed with the anti-MIG6 antibody. (C) The central
constructs for co-immunoprecipitation and mapping analyses. HCT116 cells were co-
unoprecipitated and immunoblotted with the indicated antibodies.(D) The Cdc42/Rac in-
c-MIG6 constructs for co-immunoprecipitation andmapping analyses. HCT116 cells were
munoprecipitated and immunoblottedwith the indicated antibodies. Representative blots
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with 0.2 N HCl after 30 min. The colorimetric reaction was measured in a
microplate reader at absorbance 450 nm.
2.8. Statistical analysis
Statistical signiﬁcance was determined using one-way ANOVA
followed by post-hoc tests. Values were reported as the mean with
95% conﬁdence intervals (CI. P values b0.05 were considered signif-
icant). Statistical analyses were performed using GraphPad Prism
5.0 software (GraphPad Software Inc., La Jolla, CA, USA).Fig. 2. DNAJB1 destabilizes the MIG6 protein. (A) DNAJB1 overexpression reduces the stability
either Flag-tagged wild-type DNAJB1 (DNAJB1) or mutant DNAJB1Δ180–210. Cell lysates were im
bility. si-DNAJB1s (10 pM) were transfected into HCT116 cells, and cell lysates were immunob
cells were transfected with the indicated plasmids (D) or siRNAs (E). 48 h after transfection,
were immunoblotted with the indicated antibodies. Mean ± SEM of three independent expe
analysis.3. Results
3.1. DNAJB1 binds to MIG6
To explore the regulatory mechanisms of MIG6, we ﬁrst dissected
the MIG6 interactome using yeast two-hybrid assays. A human ovary
cDNA library was screened using Gal4-fusions of full-length MIG6
(1–462 a.a.). cDNAs were isolated from positive clones and sub-
sequently, DNA sequencing was performed. Based on the sequence
analyses, we identiﬁed the heat shock protein DNAJB1 as a putative
MIG6-interacting protein (Supplementary Table S1). To validate ourof endogenous MIG6 but does not affect its mRNA levels. A549 cells were transfected with
munoblotted with the indicated antibodies. (B) DNAJB1 knockdown increases MIG6 sta-
lotted with the indicated antibodies (C–D) DNAJB1 reduces the stability of MIG6. HCT116
cells were treated with 10 μM cycloheximide (CHX) for the indicated times. Cell lysates
riments. *P b 0.01, **P b 0.05, and ***P b 0.001 compared to transfection control, ANOVA
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immunoprecipitation (co-IP) and GST pull down analyses demonstrated
that DNAJB1 or MIG6 speciﬁcally bound each other, but not the control
(Fig. 1A). Moreover, we veriﬁed an endogenous interaction between
MIG6 and DNAJB1 (Fig. 1B). To elucidate the structure and function of
the MIG6-DNAJB1 interaction, we next mapped the DNAJB1 interaction
domains for MIG6. For these experiments, the DNAJB1 protein was divid-
ed into seven fragments, and their interaction with MIG6 was evaluated
using co-IP assays (Fig. 1C). The central domain (180–210 a.a.) of
DNAJB1 was interacted with MIG6. On the other hand, the MIG6 protein
was divided into four fragments, and their interaction with DNAJB1 was
evaluatedusing co-IP assays (Fig. 1D).We found that the Cdc42/Rac inter-
action and binding (CRIB) domain of MIG6 was interacted with DNAJB1.Fig. 3.DNAJB1 enhances ubiquitin-dependent proteosomal degradation ofMIG6. (A)DNAJB1ov
transfected with Flag-tagged DNAJB1. Two days after transfection, cells were treated with M
Mean ± SEM of three independent experiments. (B) DNAJB1 overexpression increases MIG
DNAJB1 or DNAJB1Δ180–210, and Myc-tagged MIG6 as indicated. Cells were treated with MG1
the Myc antibody and immunoblotted with the HA antibody. (C) DNAJB1 knockdown diminis
were transfected with HA-tagged Ub and Myc-tagged MIG6 as indicated. Cells were treated wi
using the Myc antibody and immunoblotted with the HA antibody. (D) DNAJB1 destabilizes M
structs as indicated. Cells were treated withMG132 (10 μM) for 6 h before harvest. Total cell ex
antibody. Representative blots from three independent experiments are shown.These data collectively indicates that the central domain (180–210 a.a.)
of DNAJB1 is interacted with the CRIB domain of MIG6.
3.2. DNAJB1 destabilized MIG6 levels via protein destabilization
We further validated this interaction using dose-dependent over-
expression or knockdown of DNAJB1 on MIG6 level. Overexpression of
wild-type DNAJB1 (DNAJB1) substantially decreased MIG6 levels.
However, overexpression of the MIG6-interaction defective mutant
DNAJB1Δ180–210 failed to reduce the MIG6 protein levels. Important-
ly, DNAJB1 overexpression did not affect the level of Mig6 mRNA
(Fig. 2A). Similarly, DNJAB1 knockdown substantially increased
the level of endogenous MIG6 protein, but not its mRNA (Fig. 2B).erexpression abrogates the effect ofMG132on the stabilization ofMIG6. HCT116 cellswere
G132 (10 μM) for 6 h. Total lysates were immunoblotted with the indicated antibodies.
6 ubiquitination. HCT116 cells were transfected with HA-tagged ubiquitin, Flag-tagged
32 (10 μM) for 6 h before harvesting. Total cell extracts were immunoprecipitated using
hes MIG6 ubiquitination. HCT116 cells were transfected with si-DNAJB1. After 24 h, cells
th MG132 (10 μM) for 6 h before harvesting. Total cell extracts were immunoprecipitated
IG6 by enhancing K48-linked ubiquitination. HCT116 cells were transfected with the con-
tracts were immunoprecipitated using theMyc antibody and immunoblottedwith the HA
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protein biosynthesis) treatment showed that DNAJB1 overexpres-
sion further enhanced the effect of CHX on MIG6 destabilization
(Fig. 2C). Notably, DNAJB1 knockdown greatly diminished the nega-
tive effect of CHX on the stability of MIG6 protein, verifying a critical
role for DNAJB1 in MIG6 destabilization (Fig. 2D).
3.3. DNAJB1 enhances K48-linked ubiquitination of MIG6
Since DNAJB1 decreased the MIG6 protein level, not mRNA expres-
sion, we next examined whether DNAJB1 reduces the stability of the
MIG6 protein. TreatmentwithMG132 efﬁciently increasedMIG6 levels,
whereas DNAJB1 overexpression diminished the effect of MG132 on
MIG6 protein stabilization (Fig. 3A). This result indicates that DNAJB1
reduces MIG6 levels via protein destabilization. Fiorini et al. reported
that MIG6 protein is ubiquitynylation target for proteasome-dependent
degradation [25]. Because DNAJB1 overexpression greatly decreased
MIG6 protein stability, we next investigated whether DNAJB1 decreases
MIG6 stability by altering the ubiquitin-dependent proteasomal deg-
radationpathway. As shown in Fig. 3B, overexpressionofDNAJB1dramat-
ically increased MIG6 ubiquitination. Importantly, overexpression of
DNAJB1Δ180–210 failed to enhance the levels of MIG6 ubiquitination. Con-
sistently, DNAJB1 knockdown substantially reduced MIG6 ubiquitination
(Fig. 3C). It has been reported that several ubiquitin linkages (K6, K11,
K27, K29, K33, K48, K63) are typically associated with different cellular
functions [26]. Because K48-linked polyubiquitin chains are involved
in proteasomal degradation, whereas K63-linked polyubiquitination
leads to nonproteasomal modiﬁcation [27], we next examined whether
DNAJB1-induced ubiquitination of MIG6 is mediated by K48-linked
ubiquitination. HCT116 cells were transfected with Flag-DNAJB1 and
either wild-type HA-tagged ubiquitin or ubiquitin mutants harboringFig. 4. DNAJB1 positively regulates EGFR signaling pathway via MIG6 destabilization. (A) MIG
againstMIG6. Cell lysates were immunoblotted with the indicated antibodies. (B) The mutant
transfected into A549 cells. Cell lysates were immunoblotted with the indicated antibodies. (C
lysates were immunoblotted with the indicated antibodies. Mean ± SEM of three independe
ANOVA analysis.K48- or K63-speciﬁc ubiquitination [28]. As shown in Fig. 3D, DNAJB1-
induced MIG6 ubiquitination is induced in the presence of the K48-
speciﬁc ubiquitinmutant but not with the K63-speciﬁcmutant. These re-
sults suggest that DNAJB1 destabilizes MIG6 by enhancing K48-linked
ubiquitination of MIG6.
3.4. DNAJB1 is a positive regulator of EGFR signaling pathway via reduction
of MIG6 levels
MIG6 is a negative regulator of EGFR signaling pathway [1]. There-
fore, we next examined whether DNAJB1-mediated negative regulation
of MIG6 affects EGF receptor signaling. As consistent with previous re-
ports [2,6], overexpression of MIG6 dose-dependently decreases EGFR
levels as well as ERK1/2 phosphorylation (Fig. 4A, left panel). However,
MIG6 knockdown increased EGFR protein and ERK1/2 phosphorylation
levels (Fig. 4A, right panel). DNAJB1 overexpression reduced MIG6 pro-
tein levels and increased the levels of EGFR protein and ERK1/2 phos-
phorylation. However, mutant DNAJB1Δ180–210 did not affect the levels
of both EGFR protein and ERK1/2 phosphorylation (Fig. 4B). DNAJB1
knockdown increased MIG6 levels, which corresponded to reduced
EGFR level and ERK1/2 phosphorylation (Fig. 4C). These results indicate
that DNAJB1 is a positive regulator of EGFR signaling pathway via the
reduction of MIG6 levels.
3.5. DNJAB1 knockdown enhances the sensitivity of A549 cells to geﬁtinib
We next explored the role of DNAJB1 during activation of EGFR
signaling by EGF treatment. As expected, MIG6 is induced rapidly
upon EGFR activation, which is believed to be part of a negative feed-
back loop that regulates EGFR activation and stability (Fig. 5A). Impor-
tantly, DNAJB1 overexpression signiﬁcantly increased EGFR stability,6 inhibits EGFR signaling. A549 cells were transfected with Myc-tagged MIG6 or siRNAs
DNAJB1Δ180–210 failed to suppress EGFR signaling. Either DNAJB1 or DNAJB1Δ180–210 was
) DNAJB1 knockdown reduces EGFR signaling. A549 cells were transfected siDNAJB1. Cell
nt experiments. *P b 0.01, **P b 0.05, and ***P b 0.001 compared to transfection control,
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pression. On the other hand, mutant DNAJB1Δ180–210 did not affect to
EGF-induced EGFR activation signaling (Fig. 5B). DNAJB1 knockdown
leads to downregulation of EGFR signaling by increasing the levels of
MIG6 (Fig. 5C), verifying that DNAJB1 is a negative regulator of MIG6
in the regulation of EGF signaling. Aberrant activation of EGFR signaling
leads to tumor growth and progression [29]. Because we observed aFig. 5. DNAJB1 knockdown increases the sensitivity of A549 cells to geﬁtinib. (A) EGF rapidly a
indicated times. Cell lysates were immunoblotted with the indicated antibodies. (B) Overexpr
with indicated plasmids. After 48 h, cells were treated with EGF, and cell lysates were analyze
EGFR activation. A549 cells were transfectedwith siDNAJB1. After 48 h, cells were treatedwith E
resentative blots from three independent experiments are shown. (D)DNAJB1 knockdowndimi
After 24 h, cellswere treatedwith EGF, and cell viabilitywas determined usingMTT assays. Error
knockdown enhanced the geﬁtinib-induced apoptosis. After 24 h transfection with siRNA, cell
***P b 0.0001 using one-way ANOVA. (F) Knockdown of DNAJB1 increased the geﬁtinib-induce
with 50 μM geﬁtinib for 48 h, and analyzed by western blotting using indicated antibodies. Re
abrogates the geﬁtinib sensitivity of A549 cells. A549 cells were transfectedwith indicated plasm
usingMTT assays. Error bars indicate SD (n=3). ***P b 0.0001 using one-wayANOVA. (H) DNA
DNAJB1 siRNAs, cells were treated with geﬁtinib (50 μM) for 24 h and cell viability was determpositive role for DNAJB1 in the regulation of EGFR activation, we next
examined the function of DNAJB1 on the growth of A549 lung cancer
cells, which exhibit genomic ampliﬁcation of wild-type EGFR. EGF treat-
ment of A549 cells increased cell proliferation. However,DNAJB1 knock-
down fully abrogated the positive effect of EGF on the growth of A549
cells (Fig. 5D). A recent study demonstrated that MIG6 overexpression
overcomes geﬁtinib resistance by inhibiting EGFR signaling [30]. Finally,ctivates the EGFR signaling pathway. A549 cells were treated with 100 ng/ml EGF for the
ession of DNAJB1 enhances EGFR activation via reduction of MIG6. Cells were transfected
d by western blotting using the indicated antibodies. (C) DNAJB1 knockdown diminishes
GF, and cell lysates were analyzed bywestern blotting with the indicated antibodies. Rep-
nishes the EGF effect on the viability of A549 cells. A549 cellswere transfectedwith siRNAs.
bars indicate 95% conﬁdence intervals;**,***P b 0.0001 using one-wayANOVA. (E) DNAJB1
s were treated with 50 μM geﬁtinib for 48 h. Apoptosis was measured by Tunel assay kit.
d PARP-1 and Caspase-3 cleavage. A549 cells were transfected with DNAJB1 siRNA, treated
presentative blots from independent experiments are shown. (G) DNAJB1 overexpression
ids. After 24 h, cells were treatedwith geﬁtinib (50 μM), and cell viability was determined
JB1 knockdown enhanced the geﬁtinib sensitivity of A549 cells. After 48 h transfectionwith
ined using MTT. *** P b 0.0001 using one-way ANOVA.
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the sensitivity of A549 cells to geﬁtinib by increasing MIG6 protein
levels. As expected, geﬁtinib-induced apoptosis were enhanced by
DNAJB1 knockdown (Fig. 5E). In addition, geﬁtinib-induced PARP-1
cleavage and active caspase-3 were increased after knockdown of
DNAJB1 (Fig. 5F). DNAJB1 suppression promotes MIG6-mediated apo-
ptosis. Overexpression of DNAJB1 abolished the sensitivity of A549
cells to geﬁtinib; whereas the DNAJB1Δ180–210 mutant had negligible
effects on geﬁtinib sensitivity (Fig. 5G). Importantly, DNAJB1 knock-
down signiﬁcantly enhanced the sensitivity of A549 cells to geﬁtinib
(Fig. 5H). Collectively, these data demonstrates that reduction of
DNAJB1 enhances the sensitivity of lung cancer cells to geﬁtinib.
4. Discussion
HSPs have an important role in the unfolded protein response [31].
HSP dysregulation is implicated in a variety of human diseases, in-
cluding cancer. Thus, HSPs are highly expressed in human tumors and
often associatedwith increased chemoresistance and poor patient prog-
nosis [31]. In this context, selective inhibition of HSPs using speciﬁc in-
hibitors has been proposed as a strategy to chemosensitize cancer cells
[32,33]. DnaJ/HSP40 proteins are well-known co-chaperones that regu-
late the ATP hydrolysis activity of HSP70 [20]. However, recent research
has revealed that they function as independent chaperones, particularly
in various types of cancers [19]. Although the exact role of DnaJ/HSP40
proteins and the molecular mechanisms by which they are involved in
cancer biology need further investigation, recent studies have provided
critical clues. Our group very recently showed that DNAJB1 negatively
regulates p53 signaling through ubiquitin-mediated proteosomal deg-
radation of the tumor suppressor gene PDCD5 [24]. It appears possible
that the DnaJ/HSP40 protein family is involved in cancer development
by directly regulating the stability of proteins such as tumor sup-
pressors. Moreover, data from several studies support the notion that
DnaJ/HSP40 proteins may mediate ubiquitin-dependent proteasomal
degradation of target proteins. The DNAJ/HSP40 proteins human Hsj1
(DNAJ-like-1) and yeast Ydj1 have two putative ubiquitin-interacting
motifs (UIMs) based on bioinformatics analyses and biological experi-
ments [34–36].
Previous data have demonstrated that MIG6 acts as a tumor sup-
pressor. Thus, its downregulation is observed inmultiple human tumors
[7,37,38]. Tumor size was also inversely correlated with MIG6 expres-
sion in some cancers [38]. Based on cDNA microarray analyses, MIG6
is downregulated relative to normal tissues in patients with shorter sur-
vival times [3]. These data strongly suggest that MIG6 expression is
closely related with poor prognoses in some types of human cancer.
However, despite the strong association between MIG6 expression
and cancer, it remained unknown howMIG6 protein levels are regulat-
ed. In this study, we identiﬁed a novel protein, DNAJB1, which affected
MIG6 protein stabilization without changing its mRNA levels. These
results suggested that MIG6 expression appears to be regulated by
DNAJB1 at the post-translational level. In this study, we found that
MIG6 was dramatically stabilized in the presence of MG132, and over-
expression of DNAJB1 effectively abrogated stabilization of MIG6 stabi-
lization. Moreover, DNAJB1-enhanced proteosomal degradation of
MIG6wasmediated by polyubiquitin chains linked through the K48 res-
idue of ubiquitin, which are most commonly associated with proteins
targeted for proteosomal degradation [27]. These results provide evi-
dence that support previous studies addressing the role of DnaJ/HSP
proteins in proteosomal-dependent degradation pathways, as well as
describe a novel protein involved in MIG6 destabilization.
The tumor suppressor role of MIG 6 is important in EGFR signaling
because it is a known negative feedback regulator of EGFR [1]. EGFR is
large family of receptor tyrosine kinases (RTK) that are highly expressed
in several types of cancer, including lung, esophageal, and breast cancer
[29]. MIG6 inhibits EGFR via a two-tiered mechanism that involves re-
ceptor degradation and kinase suppression, thereby causing activationof ERK signaling [1,39,40]. Our data demonstrate that DNAJB1 positively
affects EGFR signaling bymediatingMIG6degradation. EGFR signaling is
closely related to drug resistance [29]. Selective small molecule tyrosine
kinase inhibitors (TKIs) that target EGFR, such as geﬁtinib and erlotinib,
are currently used to treat various human cancers [41]. Although these
drugs have improved progression-free and overall survival, primary as
well as acquired drug resistance eventually occurs in most, if not all,
treated patients [42,43]. Thus, drug resistance remains a problem that
affects patient survival. However, although MIG6 is involved in signal-
ing, experimental evaluation of the role of MIG6 in drug resistance in
human cancers has not been addressed [38]. A recent study showed
that MIG6 is overexpressed in prostate cancer cell lines with high geﬁ-
tinib sensitivity, but not in geﬁtinib-resistant NSCLC cell lines [44].
Based on previous reports, we hypothesized that stabilizingMIG6 by at-
tenuating DNAJB1 function may improve geﬁtinib resistance. Indeed,
we observed that DNAJB1 knockdown signiﬁcantly improved the sensi-
tivity of A549 lung cancer cell to geﬁtinib. These data suggest that mod-
ulation of DNAJB1 could be a beneﬁcial effect for geﬁtinib-resistant lung
cancer. Collectively, our data reveals the newmolecular mechanism in-
volved in regulation of EGFR signaling pathway by manipulation of
MIG6 protein via DNAJB1 as its negative regulator.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.07.024.
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